Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Avalo Therapeutics, Inc. (AVTX) had Normalized Pre-Tax Income of $-20.75M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-20.77M |
|
-- |
|
-- |
|
$19.32M |
|
$-19.32M |
|
$-1.43M |
|
$-20.75M |
|
|
Normalized Pre-Tax Income |
$-20.75M |
$-20.77M |
|
$-20.77M |
|
$-20.77M |
|
$-20.77M |
|
$-19.32M |
|
$-19.18M |
|
10.83M |
|
10.83M |
|
$-1.92 |
|
$-1.92 |
|
| Balance Sheet Financials | |
$115.19M |
|
$0.69M |
|
$11.40M |
|
$126.58M |
|
$9.26M |
|
-- |
|
$12.75M |
|
$22.01M |
|
$104.57M |
|
$94.07M |
|
$104.57M |
|
10.84M |
|
| Cash Flow Statement Financials | |
$-20.85M |
|
$-70.86M |
|
$-0.47M |
|
$134.70M |
|
$42.52M |
|
$-92.18M |
|
$5.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-91.71M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.86% |
|
-22.07% |
|
-16.40% |
|
-19.86% |
|
$9.65 |
|
$-8.47 |
|
$-1.93 |
|